Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
about
Targeting gene expression selectively in cancer cells by using the progression-elevated gene-3 promoter.Antitumor activity of an hTERT promoter-regulated tumor-selective oncolytic adenovirus in human hepatocellular carcinomaOncolytic adenoviruses: A thorny path to glioma cureChapter One---Cancer terminator viruses and approaches for enhancing therapeutic outcomes.Gene Therapies for Cancer: Strategies, Challenges and Successes.Gene therapy of liver diseases.Conditionally replicating adenoviruses for cancer treatment.Targeting telomerase-expressing cancer cells.Drug insight: Cancer cell immortality-telomerase as a target for novel cancer gene therapies.Telomerase-specific oncolytic virotherapy for human hepatocellular carcinoma.MR molecular imaging of tumours using ferritin heavy chain reporter gene expression mediated by the hTERT promoter.Oncolytic virus therapy for prostate cancer.Telomerase-specific oncolytic virotherapy for human gastrointestinal cancer.Is telomerase a viable target in cancer?Conditional expression of a suicide gene by the telomere reverse transcriptase promoter for potential post-therapeutic deletion of tumorigenesis.Assessment of Specificity of an Adenovirus Targeted to HER3/4.Oncolytic viruses: adenoviruses.Efficient virotherapy for osteosarcoma by telomerase-specific oncolytic adenovirus.Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope.Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.
P2860
Q33762359-78EA138B-0564-4965-A4CF-1C9D32ACF035Q33868732-4E9F91F5-3E84-42C9-96AF-C0E6865D3E32Q35077747-3C9D6FF7-CEA1-4825-8476-C71004DD4B42Q35142325-47CC147D-CF53-4884-8A64-783BCF7148A5Q35186312-4CEE098B-03E1-4B0C-8A50-7D6242FA7CFBQ35842662-60C3B567-B376-438F-B604-0C98654A4324Q35967313-9F79CBAD-630A-4353-809B-E8B18E23C93CQ36017631-15119323-8792-4F72-9AAE-17D8BE0414BAQ36303872-6BEF1F34-B32F-4AFA-88B1-B9425F6F2659Q37212969-04B93D00-C2C3-4B56-A312-AB4FC205BB31Q37314214-E431F2D0-68FF-4810-B9F6-9EDBB89ADEF8Q37615535-6F1F6428-BE45-49F6-879D-CA3101CA645FQ37866781-7C9BB341-EDF0-4B42-99BB-40EF23397245Q37908470-999DA2FF-4186-412D-A81C-FF8BDFC58700Q38472381-13DB2A83-986A-4A85-AF15-153376AE048CQ38645041-8F7780F0-549F-45F3-9777-D6980BC351C7Q39432063-531D6E47-0A3F-4381-8811-EF8D34E25D1EQ39613754-5F7398B7-BBEE-4650-B264-B3596F57F3ECQ40395130-90EBC6AE-4911-4B6C-BDFE-55DBAD5BB17AQ47095296-88133D26-570E-4BD7-A619-572AEFE8A00BQ47251747-6A090F9D-F42F-4D6C-B582-29A7EEAB2194
P2860
Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Conditionally replicative aden ...... tivity without liver toxicity.
@en
type
label
Conditionally replicative aden ...... tivity without liver toxicity.
@en
prefLabel
Conditionally replicative aden ...... tivity without liver toxicity.
@en
P2093
P2860
P356
P1433
P1476
Conditionally replicative aden ...... tivity without liver toxicity.
@en
P2093
Anish S Majumdar
Brian Murphy
Chris O'Sullivan
Jane S Lebkowski
John Irving
Lisa Cardoza
Michael Mok
Sandra Powell
P2860
P2888
P304
P356
10.1038/SJ.CGT.7700666
P577
2004-03-01T00:00:00Z
P5875
P6179
1019823777